Paeoniflorin Attenuates Lipopolysaccharide-Induced Cognitive Dysfunction by Inhibition of Amyloidogenesis in Mice

Int J Mol Sci. 2023 Mar 2;24(5):4838. doi: 10.3390/ijms24054838.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease, associated with progressive cognitive impairment and memory loss. In the present study, we examined the protective effects of paeoniflorin against memory loss and cognitive decline in lipopolysaccharide (LPS)-induced mice. Treatment with paeoniflorin alleviated LPS-induced neurobehavioral dysfunction, as confirmed by behavioral tests, including the T-maze test, novel-object recognition test, and Morris water maze test. LPS stimulated the amyloidogenic pathway-related proteins (amyloid precursor protein, APP; β-site APP cleavage enzyme, BACE; presenilin1, PS1; presenilin2, PS2) expression in the brain. However, paeoniflorin decreased APP, BACE, PS1, and PS2 protein levels. Therefore, paeoniflorin reverses LPS-induced cognitive impairment via inhibition of the amyloidogenic pathway in mice, which suggests that paeoniflorin may be useful in the prevention of neuroinflammation related to AD.

Keywords: Alzheimer’s disease; cognitive impairment; lipopolysaccharide; memory loss; paeoniflorin.

MeSH terms

  • Alzheimer Disease / drug therapy
  • Amyloid beta-Peptides / metabolism
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Cognitive Dysfunction* / drug therapy
  • Disease Models, Animal
  • Glucosides* / therapeutic use
  • Lipopolysaccharides
  • Maze Learning
  • Memory Disorders* / drug therapy
  • Mice
  • Mice, Transgenic
  • Monoterpenes* / therapeutic use

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Lipopolysaccharides
  • peoniflorin
  • Glucosides
  • Monoterpenes

Grants and funding

This research received no external funding.